Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711898 | 0.94 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL21480134 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL12357446 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL18701905 | 0.80 | MEN1 (0.40) | SPRMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL14110948 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL15198072 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL26031625 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL16446458 | 0.73 | CHRNB2 (0.34) | SMN1; SMN2 | |
| SCHEMBL18702146 | 0.72 | CHRM2 (0.35) | MEN1KMT2AALDH1A1CHRM2CHRM1 | |
| SCHEMBL20690443 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | SMN1; SMN2 2655/4885SPR 1/4885MEN1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.